News | EP Lab | July 30, 2021

Innovative Health Planning to Add Catheter Reprocessing for  Emerging EP Technologies 

Reprocessing can help save millions in Cath labs and EP lab costs

Innovative Health Inc. announced several new initiatives to increase savings from single-use device reprocessing in the electrophysiology (EP) lab. #HRS21 #HRS2021 #Heartrhythm21

July 30, 2021 – Innovative Health Inc. announced several new initiatives to increase savings from single-use device reprocessing in the electrophysiology (EP) lab. The company has formed an emerging technologies team, charged with developing new reprocessing technologies that will enable cost-savings to be realized on more devices, modalities and clinical areas. Simultaneously, the company has launched a clinical integration team that will be working directly with EP labs to align clinical, technological, and administrative goals in order to simultaneously optimize savings and patient care quality. 

The company made the announcement earlier July in preparation for the Heart Rhythm 2021 Scientific Sessions, the annual meeting of the  Heart Rhythm Society (HRS)

“Single-use device reprocessing has been successfully proven to generate substantial savings for participating cardiology programs,” said Innovative Health CEO Rick Ferreira. “However, we have barely scratched the surface in terms of savings. To realize higher savings, we need to continue to develop our technology and work with our partners to ensure savings are maximized. This is an important investment in the future of reprocessing.”

The announcement comes as Innovative Health is on the verge of adding several new devices to its list of reprocessing opportunities. Four submissions are under review with U.S. Food and Drug Administration (FDA), some of which are for devices that represent the newest and most advanced technology within their modalities. Such clearances will enable labs to increase their per-procedure savings by hundreds of dollars.   

Innovative Health’s investment in its newly formed emerging technologies team will also support its expansion into targeting savings opportunities outside of the EP lab. Annual savings potential in the cardiac cath lab (interventional cardiology) via reprocessing is estimated to be hundreds of millions of dollars a year. The vendor said similar to the savings that can be achieved in the EP lab. The company is expecting its first cath lab device clearance within the next few months.

Savings per procedure from reprocessing basic catheters are less than $1,000 per procedure, while savings on some diagnostic ultrasound and mapping catheters are more than $1,000 per device. Upgrading a basic EP reprocessing program to an advanced reprocessing program typically adds savings of more than $2,000 per procedure, or 100s of thousands of dollars per year, the company said.

“Innovative Health has enabled EP labs to reduce their costs considerably through single-use device reprocessing,” said Aaron DeTate, senior director of clinical integration at Innovative Health. “We are excited to take these savings across the hall to the cath lab and offer similar financial benefits to our colleagues in interventional cardiology.” 

For more information: innovative-health.com

Find more EP device news

Find more HRS 2021 conference news

Related Content

Feature | Cath Lab | September 14, 2021 | By Aaron Detate and Lars Thording
In the electrophysiology (EP) lab, hundreds
An example of the Medis QCA angiography imaging derived fractional flow reserve (FFR) assessment. This technology removes the need for pressure wires and adenosine used in traditional FFR assessments of the coronary arteries.

An example of the Medis QCA angiography imaging derived fractional flow reserve (FFR) assessment. This technology removes the need for pressure wires and adenosine used in traditional FFR assessments of the coronary arteries.

News | Cath Lab | July 22, 2021
July 22, 2021 — Medis Medical Imaging is partnering with CORRIB Core Lab and Sinomed in randomized clinical trial of
ast End Medical announced it received U.S. Food and Drug Administration (FDA) clearance for the company's SafeCross Transseptal Radiofrequency (RF) Puncture and Steerable Balloon Introducer System. The 3-in-1 system, which includes a steerable introducer sheath with an ultra-visible positioning balloon and radiofrequency (RF) puncture dilator, aims to provide a predictable and safe solution for electrophysiology (EP) and structural heart interventions requiring left atrial access.
News | Cath Lab | July 14, 2021
July 13, 2021 — East End Medical announced it received U.S.
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone. #SCAI21 #SCAI2021 Creating a card0-renal program.

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone.

Feature | Cath Lab | May 14, 2021 | By Dave Fornell, Editor
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal fun
Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting proc

Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.

News | Cath Lab | May 12, 2021
May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has
SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI.

Feature | Cath Lab | May 06, 2021 | By Dave Fornell, Editor
April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from
Most Stable Ischemic Heart Disease Patients Did Not Meet ISCHEMIA Trial Enrollment Criteria, raising questions about its application in real-world practice. #SCAI2021 Getty Images

Getty Images

News | Cath Lab | May 03, 2021
May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for sta
New study demonstrates depression, HIV, mental health, obesity, alcohol and drug abuse are risk factors on most common type of heart disease in young black patients. Photo by Dave Fornell
News | Cath Lab | April 29, 2021
April 29, 2021 – A retrospective analysis of risk factors for coronary artery disease (CAD) in young African American
There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

News | Cath Lab | April 28, 2021
April 28, 2021 – Results from a retrospective observational study, presented today at...